Firefly Neuroscience And Bright Minds Advance Phase 1 Study With AI-Driven Data Analysis
Firefly Neuroscience, Inc. (NASDAQ:AIFF) announced a collaboration with Bright Minds Biosciences Inc. (NASDAQ:DRUG) to analyze data from the first-in-human Phase 1 study of BMB-101, Bright Minds’ lead compound for neuropsychiatric disorders and refractory epilepsy. Firefly employed its advanced AI-powered BNA technology to analyze the qEEG (Quantitative Electroencephalogram) data collected through EEG headsets provided by Zeto Inc.
Why It Matters: The study demonstrated positive results, with subjects …